NasdaqGM:IOVABiotechs
Will FDA’s RP1 Setback Refocus Iovance Biotherapeutics' (IOVA) Post-Checkpoint Melanoma Narrative?
Earlier in April, analyst firm Chardan reaffirmed its positive view on Iovance Biotherapeutics after the FDA issued a second complete response letter for Replimune’s RP1 in combination with nivolumab in adults with unresectable advanced cutaneous melanoma post anti-PD-1 therapy.
This regulatory setback for a rival therapy has been interpreted as strengthening the near-term competitive position of Iovance’s Amtagvi in the post-checkpoint melanoma treatment landscape.
With this potential...